Biotronik-Safety and Performance Registry for an All-comers Diabetic Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice-III Asia
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2017
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms BIOFLOW III Asia
- Sponsors BIOTRONIK
- 26 Sep 2017 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned number of patients changed from 880 to 364.
- 15 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Apr 2017.